ETFs Legend Biotech Corporation

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-12 EDT			5-day change	1st Jan Change
50.72 ^USD	+1.95%		-6.16%	-15.71%

09-04	Transcript : Legend Biotech Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 02:35 PM
08-27	Legend Biotech Says China's National Medical Products Administration Approves Cell Therapy Product to Treat Multiple Myeloma	MT

ETFs positioned on Legend Biotech Corporation

Name	Weight	AuM	1st Jan change	Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD	3.08%	4 M€	-27.92%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD	1.18%	2 M€	-14.14%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	0.99%	1 M€	-20.08%	-
ADVISORSHARES ALPHA DNA EQUITY SENTIMENT ETF - USD	0.95%	11 M€	-6.03%	-
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.58%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.51%	0 M€	0.00%	-
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	0.24%	2 M€	-.--%
LEVERAGE SHARES -3X SHORT CHINA ETP SECURITIES - USD	0.12%	0 M€	0.00%	-
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR	0.06%	2,955 M€	+7.36%
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR	0.06%	484 M€	+8.12%	-
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD	0.06%	159 M€	+7.09%	-
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD	0.05%	4 M€	-4.41%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.02%	99 M€	+3.38%	-
DEMOCRACY INTERNATIONAL FUND ETF - USD	0.00%	7 M€	+7.11%	-
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY	0.00%	16 M€	+4.87%

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,200

Sector

Biotechnology & Medical Research

Calendar

2024-11-17 - Q3 2024 Earnings Release (Projected)

More about the company